Promising directions for the use of intravenous fosfomycin in children

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Department; Moscow; Russia

Background: This review presents a brief overview of fosfomycin’s spectrum of activity; its efficacy in children; safety data; and information on ongoing clinical trials in children; which are defining more precise pharmacokinetic safety parameters across different age groups. These studies will provide additional information on expanding the indications for fosfomycin use in children.

Objective: Provision of a substantiated opinion on the role of fosfomycin in improving antimicrobial treatment outcomes for infections caused by resistant microorganisms in children; based on available evidence.

Conclusion: Fosfomycin in intravenous dosage form can be used to treat infections caused by resistant microorganisms as part of combination antimicrobial therapy. It is particularly important to note that in the adult population; increased survival was demonstrated for bacteremia caused by KPC carbapenemase-producing K. pneumoniae with the use of a combination of fosfomycin and ceftazidime avibactam compared with ceftazidime avibactam alone. Fosfomycin has demonstrated synergistic and additive activity in vitro in combination with various classes of antibiotics; particularly beta-lactams; daptomycin; polymyxins; and aminoglycosides. It should be preferred as part of combination antimicrobial therapy for the treatment of infections associated with invasive implantable devices due to its activity against biofilms. For the treatment of infections caused by microbes resistant to multiple antibiotics in children; high doses of intravenous fosfomycin (more than 200 mg/kg/day) should be used. Improving the safety profile of high-dose intravenous fosfomycin in children is possible with regular monitoring of electrolyte levels; especially in neonates and/or critically ill children with renal failure.

Full Text

Restricted Access

About the authors

Anna V. Vlasova

Morozov Children’s City Clinical Hospital; Russian Medical Academy of Continuous Professional Education; Research Institute for Healthcare Organization and Medical Management

Author for correspondence.
Email: annavlasova75@mail.ru
ORCID iD: 0000-0001-5272-2070
SPIN-code: 5248-6411

Dr. Sci. (Med.); Head of the Clinical Pharmacology Department; Morozov Children’s City Clinical Hospital; Moscow Healthcare Department; Associate Professor; B.E. Votchal Department of Clinical Pharmacology and Therapy; Russian Medical Academy of Continuous Professional Education; Leading Specialist; Clinical Pharmacology Department; Research Institute for Healthcare Organization and Medical Management; Moscow Healthcare Department

Russian Federation, Moscow; Moscow; Moscow

T. R. Kameneva

Research Institute for Healthcare Organization and Medical Management; Federal Research and Clinical Center of Resuscitation and Rehabilitation

Email: tkameneva@fnkcrr.ru
ORCID iD: 0000-0003-3957-5015
SPIN-code: 8625-7540

Cand. Sci. (Med.); OMD for Clinical Pharmacology; Research Institute for Healthcare Organization and Medical Management; Federal Research and Clinical Center of Resuscitation and Rehabilitation

Russian Federation, Moscow; Moscow

S. V. Yakovlev

Russian Medical Academy of Continuous Professional Education; S.S. Yudin City Clinical Hospital of the Moscow Healthcare Department

Email: antimicrob@yandex.ru
SPIN-code: 9313-1453

Dr. Sci. (Med.); Professor; B.E. Votchal Department of Clinical Pharmacology and Therapy; Russian Medical Academy of Continuous Professional Education; Clinical Pharmacologist; S.S. Yudin City Clinical Hospital; Moscow Healthcare Department

Russian Federation, Moscow; Moscow

References

  1. Geneva; W. & World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed. 2017.
  2. Hendlin D. et al. Phosphonomycin; a new antibiotic produced by strains of streptomyces. Science. 1969;166:122–123. https://dx.doi.org/10.1126/science.166.3901.122
  3. Williams P.C. Potential of fosfomycin in treating multidrug‐resistant infections in children. J PaediatrChild Health. 2020;56:864–872. https://dx.doi.org/10.1111/jpc.14883
  4. Falagas M.E.; Athanasaki F.; Voulgaris G.L.; et al. Resistance to fosfomycin: mechanisms; frequency and clinical consequences. Int J Antimicrob. Agents. 2019;53:22–28. https://dx.doi.org/10.1016/j.ijantimicag.2018.09.013
  5. Drusano G. et al. The combination of fosfomycin plus meropenem is synergistic for Pseudomonas aeruginosa PAO1 in a hollow-fiber infection model. Antimicrob Agents Chemother. 2018;62:10–1128. https://dx.doi.org/10.1128/AAC.01682-18
  6. Ito R. et al. Widespread fosfomycin resistance in Gram-negative bacteria attributable to the chromosomal fosA gene. MBio 2017;8:10–1128. https://dx.doi.org/10.1128/mBio.00749-17
  7. Dimopoulos G. et al. Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens? Expert Rev Anti Infect Ther. 2019;17:201–210. https://dx.doi.org/10.1080/14787210.2019.1573669
  8. Kadner R.J.; Winkler H.H. Isolation and characterization of mutations affecting the transport of hexose phosphates in Escherichia coli. J Bacteriol. 1973;113:895–900. https://dx.doi.org/10.1128/jb.113.2.895-900.1973
  9. Grabein B.; Graninger W.; Baño J.R.; et al. Intravenous fosfomycin – back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect. 2017;23:363–372. https://dx.doi.org/10.1016/j.cmi.2016.12.005
  10. Obiero C. et al. Fosfomycin as a potential treatment for neonatal sepsis an open label randomised clinical trial evaluating safety and pharmacokinetics. Arch Dis Childhood. 2022;107(9).
  11. Falagas M.E.; Vouloumanou E.K.; Samonis G.; Vardakas K.Z. Fosfomycin. Clin Microbiol Rev. 2016;29:321–347. https://dx.doi.org/10.1128/CMR.00068-15
  12. European Medicines Agency. Product information as Approved by the CHMP on 26 March 2020; pending endorsement by the European Commission; 2020. Available: https://www.ema.europa.eu/en/documents/referral/fosfomycin-article-31-referral-annex-iii_en.pdf [Accessed 18 Jun 2020].
  13. Bodmann K.-F. et al. Real-World Use; Effectiveness; and Safety of Intravenous Fosfomycin: The FORTRESS Study. Infect Dis Ther. 2025;14(4):765–791. https://dx.doi.org/10.1007/s40121-025-01125-2
  14. Antonello R.M. et al. Fosfomycin as partner drug for systemic infection management. A systematic review of its synergistic properties from in vitro and in vivo studies. Antibiotics. 2020;9(8):500. https://dx.doi.org/10.3390/antibiotics9080500
  15. MacGowan A.P. et al. The pharmacodynamics of fosfomycin in combination with meropenem against Klebsiella pneumoniae studied in an in vitro model of infection. J Antimicrob Chemother. 2025;80:967–975. https://dx.doi.org/10.1093/jac/dkaf020
  16. Ariza J. et al. Executive summary of management of prosthetic joint infections. Clinical practice guidelines by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Enfermedades Infecc. Microbiol Clin. 2017;35(3):189–195. https://dx.doi.org/10.1016/j.eimc.2016.08.012
  17. Garcia de la Maria C. et al. Emerging issues on Staphylococcus aureus endocarditis and the role in therapy of daptomycin plus fosfomycin. Expert Rev. Anti Infect Ther. 2023;21:281–293. https://dx.doi.org/10.1080/14787210.2023.2174969
  18. Gatti M.; Viaggi B.; Rossolini G.M.; Pea F.; Viale P. Targeted therapy of severe infections caused by Staphylococcus aureus in critically ill adult patients: a multidisciplinary proposal of therapeutic algorithms based on real-world evidence. Microorganisms. 2023;11(2):394. https://dx.doi.org/10.3390/microorganisms11020394
  19. Herrera-Hidalgo L. et al. Treatment of Enterococcus faecalis infective endocarditis: a continuing challenge. Antibiotics. 2023;12(4):704. https://dx.doi.org/10.3390/antibiotics12040704
  20. Klein M. et al. German guidelines on community-acquired acute bacterial meningitis in adults. Neurol Res Pract. 2023;5(1):44. https://dx.doi.org/10.1186/s42466-023-00264-6
  21. Kühnen E.; Pfeifer G.; Frenkel C. Penetration of fosfomycin into cerebrospinal fluid across non-inflamed and inflamed meninges. Infection. 1987;15(6):422–424. https://dx.doi.org/10.1007/BF01647220
  22. Oliva A. et al. New antimicrobials and new therapy strategies for endocarditis: weapons that should be defended. J Clin Med. 2023;12(24):7693. https://dx.doi.org/10.3390/jcm12247693
  23. Rademacher J. et al. Key summary of German national guideline for adult patients with nosocomial pneumonia-Update 2024 Funding number at the Federal Joint Committee (G-BA): 01VSF22007. Infection. 2024;52(6):2531–2545. https://dx.doi.org/10.1007/s15010-024-02358-y
  24. Sojo-Dorado J. et al. Effectiveness of fosfomycin for the treatment of multidrug-resistant Escherichia coli bacteremic urinary tract infections: a randomized clinical trial. JAMA Netw Open. 2022;5(1):e2137277. https://dx.doi.org/10.1001/jamanetworkopen.2021.37277
  25. Tseng T.-C. et al. The combination of daptomycin with fosfomycin is more effective than daptomycin alone in reducing mortality of vancomycin-resistant enterococcal bloodstream infections: a retrospective; comparative cohort study. Infect. Dis Ther. 2023;12(2):589–606. https://dx.doi.org/10.1007/s40121-022-00754-1
  26. Van de Beek D. et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016; 22 Suppl 3:S37–S62. https://dx.doi.org/10.1016/j.cmi.2016.01.007
  27. Oliva A. et al. Effect of ceftazidime/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae: results from a multicentre retrospective study. JAC-Antimicrob Resist. 2022;4(6):dlac121. https://dx.doi.org/10.1093/jacamr/dlac121
  28. Putensen C. et al. Current clinical use of intravenous fosfomycin in ICU patients in two European countries. Infection. 2019;47(5):827–836. https://dx.doi.org/10.1007/s15010-019-01323-4
  29. Schintler M.V. et al. High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimicrob Chemother. 2009;64(3):574–578. https://dx.doi.org/10.1093/jac/dkp230
  30. Docobo-Perez F. et al. Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. Antimicrob. Agents Chemother. 2015;59(9):5602–5610. https://dx.doi.org/10.1128/ AAC.00752-15
  31. König C. et al. Cerebrospinal fluid penetration of fosfomycin in patients with ventriculitis: An observational study. Ann Clin Microbiol Antimicrob. 2023;22(1):29. https://dx.doi.org/10.1186/s12941-023-00572-4
  32. Darlow C.A. et al. Amikacin combined with fosfomycin for treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance. Antimicrob Agents Chemother. 2021;65(7):10–1128. https://dx.doi.org/10.1128/AAC.00293-21
  33. Garcia E. et al. Evaluation strategies for triple‐drug combinations against carbapenemase‐producing Klebsiella pneumoniae in an in vitro hollow‐fiber infection model. Clin Pharmacol Ther. 2021;109(4):1074–1080. https://dx.doi.org/10.1002/cpt.2197
  34. Wang S. et al. Pharmacodynamics of linezolid plus fosfomycin against vancomycin–resistant Enterococcus faecium in a hollow fiber infection model. Front Microbiol. 2021;12:779885. https://dx.doi.org/10.3389/fmicb.2021.779885
  35. Chen T.-T.; Chang Y.-F.; Wu Y.-C. Clinical use of intravenous fosfomycin in critical care patients in Taiwan. Pathogens. 2023;12(6):841. https://dx.doi.org/10.3390/pathogens12060841
  36. Zhanel G. et al. Real-life experience with IV fosfomycin in Canada: Results from the Canadian LEadership on Antimicrobial Real-life usage (CLEAR) registry. J Glob Antimicrob Resist. 2023;33:171–176. https://dx.doi.org/10.1016/j.jgar.2023.03.010
  37. Grillo S. et al. Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial. Nat Med. 2023;29(10):2518–2525. https://dx.doi.org/10.1038/s41591-023-02569-0
  38. Gennari F.J. Disorders of potassium homeostasis: hypokalemia and hyperkalemia. Crit Care Clin. 2002;18:273–288.
  39. Jansen M.-N. et al. Beta-lactam-associated hypokalemia. J Int Med Res. 2024;52(8):03000605241253447. https://dx.doi.org/10.1177/03000605241253447
  40. Cañamares-Orbis I.; Silva J.T.; López-Medrano F.; Aguado J. M. Is high-dose intravenous fosfomycin safe for the treatment of patients prone to heart failure? Enfermedades Infecc. Microbiol. Clínica. 2014;33(4):294–294. https://dx.doi.org/10.1016/j.eimc.2014.07.005
  41. Florent A.; Chichmanian R.-M.; Cua E.; Pulcini C. Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents. 2011;37(1):82–3. https://dx.doi.org/10.1016/j.ijantimicag.2010.09.002
  42. Tamma P.D. et al. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2024 Aug 7;ciae403. https://dx.doi.org/10.1093/cid/ciae403
  43. Obiero C.W. et al. Randomised controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload. Arch Dis Child. 2022;107(9);802–810. doi: 10.1136/archdischild-2021-322483
  44. Kane Z. et al. IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis. J Antimicrob Chemother. 2021;76(7):1855–1864. https://dx.doi.org/10.1093/jac/dkab083
  45. Molina M.; Olay T.; Ouero J. Pharmacodynamic Data on Fosfomycin in Underweight Infants. Chemotherapy. 1977;23 Suppl 1:217–222. https://dx.doi.org/10.1159/000222051
  46. Jochum F. et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: fluid and electrolytes. Clin Nutr. 2018;37 (6 Pt B):2344–2353. https://dx.doi.org/10.1016/j.clnu.2018.06.948.
  47. Brossier D.W. et al. ESPNIC clinical practice guidelines: intravenous maintenance fluid therapy in acute and critically ill children – a systematic review and meta-analysis. Intensive Care Med. 2022;48(12):1691–1708. https://dx.doi.org/10.1007/s00134-022-06882-z
  48. Sürmelioğlu N.; Çetinkaya F.; Gök M.G.; et al. Hypernatremia and hypokalemia induced by intravenous fosfomycin therapy in critically ill patients: A Retrospective Study. J Crit Care 2024;81:154670.
  49. Noel A.; Attwood M.; Bowker K.; MacGowan A. The pharmacodynamics of fosfomycin against Staphylococcus aureus studied in an in vitro model of infection. Int J Antimicrob Agents. 2020;56(1):105985. https://dx.doi.org/10.1016/j.ijantimicag.2020.105985
  50. Pfausler B. et al. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J Antimicrob Chemother. 2004;53(5):848–852. https://dx.doi.org/10.1093/jac/dkh158

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Bionika Media